Ningxia Zhongke Biotechnology Co., Ltd.
600165.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥2 | CN¥2 | CN¥5 | CN¥9 |
| - Cash | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| + Debt | CN¥0 | CN¥1 | CN¥1 | CN¥1 |
| Enterprise Value | CN¥2 | CN¥3 | CN¥6 | CN¥10 |
| Revenue | CN¥0 | CN¥0 | CN¥1 | CN¥0 |
| % Growth | 20.9% | -58.1% | 254% | – |
| Gross Profit | -CN¥0 | -CN¥0 | CN¥0 | CN¥0 |
| % Margin | -19.5% | -47.1% | 11.1% | 12.4% |
| EBITDA | -CN¥0 | -CN¥0 | CN¥0 | -CN¥0 |
| % Margin | -88.7% | -82.3% | 7.2% | -69.9% |
| Net Income | -CN¥1 | -CN¥0 | -CN¥0 | -CN¥0 |
| % Margin | -156.1% | -162.9% | -25% | -15.6% |
| EPS Diluted | -0.79 | -0.68 | -0.25 | -0.044 |
| % Growth | -16.2% | -172% | -472.1% | – |
| Operating Cash Flow | -CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| Capital Expenditures | -CN¥0 | -CN¥0 | -CN¥0 | -CN¥0 |
| Free Cash Flow | -CN¥0 | -CN¥0 | -CN¥0 | -CN¥0 |